



May 6, 2024

✓ **BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

**Re: Appointment of Independent Directors.**

We are pleased to inform you that at its meeting held today i.e. May 6, 2024, the Board of Directors appointed Mr. Jeffrey Kindler (DIN: 10592395) and Mr. Alfonso Zulueta (DIN: 10597962), as Independent Directors of the Company effective May 6, 2024.

Disclosures in compliance with Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of appointment of Independent Directors are enclosed as **Annexure - 'A'**.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The Board meeting commenced at 2.30 p.m. (IST) and concluded at 8.30 p.m. (IST).

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**

**Encl: a/a.**



**ANNEXURE - 'A'**

**Particulars as per Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.**

<b>Sl. No.</b>	<b>Particulars</b>	<b>Description</b>
1.	reasons for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	<p>i. Appointment of Mr. Jeffrey Kindler (DIN: 10592395), as Independent Director of the Company.</p> <p>ii. Appointment of Mr. Alfonso Zulueta (DIN: 10597962), as Independent Director of the Company.</p>
2.	dates of appointment/re-appointment /cessation & terms of appointment/re-appointment;	<p>i. The appointment of Mr. Jeffrey Kindler is for a term of 5 years, effective May 6, 2024.</p> <p>ii. The appointment of Mr. Alfonso Zulueta is for a term of 5 years, effective May 6, 2024.</p>
3.	brief profiles;	<p>i. Mr. Jeffrey Kindler, 68, has completed a Bachelor of Arts degree (Summa cum Laude) from Tufts University, USA and a Juris Doctor degree (Magna cum Laude) from Harvard Law School, USA. He served as a law clerk to Justice William J. Brennan, Jr. of the United States Supreme Court.</p> <p>Mr. Kindler is an experienced healthcare executive, investor and advisor. He brings over four decades of business experience and has held leadership positions at some of the world's most recognized companies including Pfizer, where he served as Chairman &amp; Chief Executive Officer, as well as McDonald's Corporation and General Electric Company. Before that, he was a partner at the law firm of Williams &amp; Connolly.</p> <p>Mr. Kindler is currently CEO of Centrexion Therapeutics, a privately held biotechnology company, and a Senior Advisor to Blackstone. He has a deep understanding of multinational corporate matters including regulations, litigations, compliance, crisis management, brand, franchise management, executive leadership and mergers &amp; acquisitions. Mr. Kindler is Chairman of the Talent &amp; Compensation Committee of Perrigo Pharmaceuticals; Chairman of the Audit Committee and Member of Compensation Committee of Precigen Inc.; Chairman of the Compensation Committee of Terns Pharmaceuticals; and a member of the Audit and Compensation Committees of Jazz at Lincoln Center.</p> <p>ii. Mr. Alfonso Zuleta, 61, completed an Economics undergraduate degree from De LA Salle University, Manila, where he was conferred the 2023 Outstanding Alumnus Award. He received MBA degree in Marketing/Finance from University of Virginia, USA.</p>



		<p>Mr. Zulueta spent over three decades in various roles of increasing responsibility with Eli Lilly and Company, a global pharmaceutical company, including as Vice President of Global Marketing, President of Global Oncology and Critical Care Products and most recently, as President of International responsible for all geographies outside the United States and Canada. He also served as a corporate officer and member of Eli Lilly and Company's Executive Committee. Mr. Zulueta previously served as member of the board of the European Federation of Pharmaceutical Industries and Associations and the U.S.-Japan Business Council.</p> <p>Mr. Zulueta currently serves as Non-Executive Chairman of the board of directors of Interpharma Investments Limited, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia. He is also CEO/Owner of CZ Ventures, a company focused on start-up investments. Mr. Zulueta serves as a director of Glooko, Inc., a provider of connected care software solutions for persons with chronic conditions and of CTS Corporation, a leading global designer and manufacturer of sensors, actuators and electronic components. He previously served as a director of Amarin Corporation, Syneos Health, Inc. and Calidi Biotherapeutics, Inc.</p> <p>Mr. Zulueta serves on a number of committees of boards including Audit, Compensation and ESG.</p>
4.	disclosure of relationships between directors	<p>i. Mr. Jeffrey Kindler is not related to any director on the Board of the Company.</p> <p>ii. Mr. Alfonso Zulueta is not related to any director on the Board of the Company.</p>

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**